Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHOK PATEL

NPI
1093809576
CMS profile
276954
Location
TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,910.62

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHOK PATEL

NPI 1093809576 · CMS profile ID 276954

TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093809576?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093809576?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093809576?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1093809576?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $6,910.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $18.8512/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241378416 CMS
Otsuka America Pharmaceutical, Inc. $2,106.0011/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1227446382 CMS
Otsuka America Pharmaceutical, Inc. $19.3211/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227446379 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $21.0510/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241378414 CMS
Life Molecular Imaging Ltd $7.2508/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254592372 CMS
ABBVIE INC. $17.4807/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203495330 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19.9407/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241378412 CMS
Eisai Inc. $18.3006/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244464095 CMS
Otsuka America Pharmaceutical, Inc. $351.0006/06/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1227446375 CMS
Otsuka America Pharmaceutical, Inc. $2,106.0005/23/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1227446370 CMS
ABBVIE INC. $16.4605/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203495325 CMS
Otsuka America Pharmaceutical, Inc. $15.2205/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227446367 CMS
ABBVIE INC. $13.6704/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203495320 CMS
ABBVIE INC. $13.9504/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203495315 CMS
Eisai Inc. $17.5104/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244464091 CMS
ABBVIE INC. $9.0903/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203495308 CMS
ABBVIE INC. $18.2202/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203495303 CMS
Otsuka America Pharmaceutical, Inc. $2,106.0002/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1227446364 CMS
Otsuka America Pharmaceutical, Inc. $15.3102/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227446360 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.42 66
PY2020 $2,969.84 33
PY2021 $7,553.27 35
PY2022 $6,054.38 18
PY2023 $14,560.76 55
PY2024 $22,723.92 31
PY2025 $6,910.62 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,752.51 11
PY2025 Principal investigator $1,229,009.00 130
PY2024 Principal investigator $3,194,861.98 28
PY2023 Recipient $355.00 1
PY2023 Principal investigator $1,914,939.19 59
PY2022 Recipient $1,248.00 4
PY2022 Principal investigator $1,105,512.02 75
PY2021 Recipient $13,374.00 3
PY2021 Principal investigator $1,695,784.21 81
PY2020 Recipient $6,288.97 21
PY2020 Principal investigator $1,118,610.73 104
PY2019 Recipient $18,854.85 12
PY2019 Principal investigator $1,138,230.38 171

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

84 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $482.00 12/31/2021 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004499
Principal investigator 1 Allergan, Inc. $200.00 12/31/2021 Non-covered Recipient Entity
BIOLOGY BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 789004501
Principal investigator 1 Merck Sharp & Dohme Corporation $62.26 12/31/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 848765101
Principal investigator 1 ITI, Inc. $2,811.55 12/23/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 830298691
Principal investigator 1 Eisai Inc. $13,033.24 12/20/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495571
Principal investigator 1 ITI, Inc. $3,305.99 12/17/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 830298371
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,500.00 12/16/2021 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
15-AVP-786-303 No dispute reported 06/30/2026 807077015
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,926.15 12/07/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 837698185
Principal investigator 1 Allergan, Inc. $1,500.00 12/02/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004497
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,090.00 11/24/2021 Non-covered Recipient Entity
VANTAGE CLINICAL TRIALS
18-AVP-786-207 No dispute reported 06/30/2026 807079703
Principal investigator 1 Eisai Inc. $20,825.68 11/19/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495569
Principal investigator 1 ITI, Inc. $2,325.00 11/19/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 830297985
Principal investigator 1 ITI, Inc. $8,450.00 10/29/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH PC
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 830297357
Principal investigator 1 Allergan, Inc. $3,020.13 10/25/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004495
Principal investigator 1 Eisai Inc. $9,365.00 10/20/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495575
Principal investigator 1 Allergan, Inc. $3,000.00 10/14/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004493
Principal investigator 1 Allergan, Inc. $7,353.00 10/13/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004489
Principal investigator 1 Allergan, Inc. $8,337.15 10/13/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004491
Principal investigator 1 Avanir Pharmaceuticals, Inc. $4,958.05 10/05/2021 Non-covered Recipient Entity
VANTAGE CLINICAL TRIALS
18-AVP-786-207 No dispute reported 06/30/2026 807079181
Principal investigator 1 Eli Lilly and Company $429.00 10/05/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 935508737
Principal investigator 1 Eli Lilly and Company $245.00 10/05/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 935509267
Principal investigator 1 Eisai Inc. $3,035.36 09/24/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495567
Principal investigator 1 Allergan, Inc. $1,000.00 09/14/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789004485
Principal investigator 1 Allergan, Inc. $551.00 09/14/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004487
Principal investigator 1 Allergan, Inc. $1,000.00 09/07/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004479
Principal investigator 1 Allergan, Inc. $2,688.33 09/07/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004481
Principal investigator 1 Allergan, Inc. $2,594.47 09/07/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004483
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $8,000.00 08/25/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder No dispute reported 06/30/2026 851026911
Principal investigator 1 Eisai Inc. $16,119.54 08/20/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495573
Recipient Eli Lilly and Company $13,174.00 08/17/2021 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 935508367
Principal investigator 1 Allergan, Inc. $3,676.50 08/13/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004477
Principal investigator 1 Eisai Inc. $5,306.40 07/20/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495559
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $3,000.00 07/07/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 844174691
Principal investigator 1 ACADIA Pharmaceuticals Inc $24.55 07/06/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 837697623
Principal investigator 1 Allergan, Inc. $5,000.00 07/01/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004473
Principal investigator 1 Allergan, Inc. $50.00 07/01/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004475
Recipient Eli Lilly and Company $50.00 06/30/2021 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 935508369
Principal investigator 1 Eli Lilly and Company $406,907.31 06/29/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 935508623
Principal investigator 1 Allergan, Inc. $1,500.00 06/28/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004471
Principal investigator 1 Allergan, Inc. $1,000.00 06/24/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 789004463
Principal investigator 1 Allergan, Inc. $750.00 06/24/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 789004465
Principal investigator 1 Allergan, Inc. $856.00 06/24/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 789004467
Principal investigator 1 Allergan, Inc. $1,000.00 06/24/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 789004469
Principal investigator 1 Allergan, Inc. $2,701.65 06/15/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789004461
Principal investigator 1 Allergan, Inc. $1,044.60 06/09/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004459
Principal investigator 1 Allergan, Inc. $1,800.00 06/08/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004457
Principal investigator 1 Eli Lilly and Company $50.00 05/31/2021 Non-covered Recipient Entity
COMPASS RESEARCH EAST LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 935508641
Principal investigator 1 Eli Lilly and Company $50.00 05/31/2021 Non-covered Recipient Entity
INTEND RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 935509043
Principal investigator 1 Eli Lilly and Company $50.00 05/31/2021 Non-covered Recipient Entity
NEW ENGLAND RESEARCH ASSOCIATES LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 935509105
Principal investigator 1 Allergan, Inc. $551.00 05/17/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004455
Principal investigator 1 Eli Lilly and Company $39.00 05/10/2021 Non-covered Recipient Entity
NORTHWESTERN UNIVERSITY
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 935508699
Principal investigator 1 Eli Lilly and Company $31.00 05/10/2021 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 935508823
Principal investigator 1 Eli Lilly and Company $50.00 04/30/2021 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE NETWORK INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 935508347
Principal investigator 1 Eli Lilly and Company $50.00 04/30/2021 Non-covered Recipient Entity
SAMY METYAS MD, INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 935508719
Principal investigator 1 Eli Lilly and Company $350.00 04/30/2021 Non-covered Recipient Entity
JULIE B SCHWARTZBARD MD PA
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 935509051
Principal investigator 1 ACADIA Pharmaceuticals Inc $6,499.00 04/19/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 837697457
Principal investigator 1 Allergan, Inc. $3,420.00 04/14/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004453
Principal investigator 1 Allergan, Inc. $11,708.75 04/13/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004451
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,900.00 04/08/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-056 No dispute reported 06/30/2026 837697435
Principal investigator 1 Eli Lilly and Company $49.00 04/08/2021 Non-covered Recipient Entity
LCGK RSRCH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 935508977
Principal investigator 1 Allergan, Inc. $1,014.60 03/17/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789004447
Principal investigator 1 Allergan, Inc. $9,365.10 03/17/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004449
Principal investigator 1 Allergan, Inc. $20,261.60 03/15/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004445
Principal investigator 1 Eisai Inc. $23,164.12 03/10/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495563
Principal investigator 1 Eisai Inc. $4,708.80 02/23/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495561
Recipient Eli Lilly and Company $150.00 02/22/2021 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 935509203
Principal investigator 1 Amgen Inc. $22,058.00 02/20/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 830986863
Principal investigator 1 Allergan, Inc. $16,266.85 02/18/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004443
Principal investigator 1 Eli Lilly and Company $406,566.00 02/17/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 935508423
Principal investigator 1 Eli Lilly and Company $6,999.00 02/16/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 935508575
Principal investigator 1 Allergan, Inc. $1,190.35 02/15/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789004439
Principal investigator 1 Allergan, Inc. $24,033.10 02/15/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004441
Principal investigator 1 ACADIA Pharmaceuticals Inc $7,053.08 02/05/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ACP-103-063 No dispute reported 06/30/2026 837697189
Principal investigator 1 Avanir Pharmaceuticals, Inc. $4,000.00 02/05/2021 Non-covered Recipient Entity
BIOBEHAVIORAL HEALTH
17-AVP-786-305 No dispute reported 06/30/2026 807075149
Principal investigator 1 Eisai Inc. $12,404.70 02/05/2021 Non-covered Recipient Entity
BIO-BEHAVIORAL HEALTH
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 840495565
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $504,167.85 02/03/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 844172433
Principal investigator 1 Allergan, Inc. $19,730.55 02/01/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789004437
Principal investigator 1 Eli Lilly and Company $3,404.00 01/29/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3451838 IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE No dispute reported 06/30/2026 935508327
Principal investigator 1 Allergan, Inc. $8,346.70 01/20/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004435
Principal investigator 1 Amgen Inc. $4,500.00 01/20/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 830986867
Principal investigator 1 Eli Lilly and Company $2,994.00 01/15/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY No dispute reported 06/30/2026 935508329
Principal investigator 1 Allergan, Inc. $738.15 01/14/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 789004433
Principal investigator 1 Allergan, Inc. $1,500.00 01/05/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 789004431
Principal investigator 1 Amgen Inc. $695.00 01/04/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Work Productivity Study No dispute reported 06/30/2026 830986865